A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of GrafixCORE for the Treatment of Complex Diabetic Foot Wounds With Exposed Tendon and or Bone
Phase of Trial: Phase IV
Latest Information Update: 06 Oct 2016
At a glance
- Drugs Placental-derived mesenchymal stem cell therapy Osiris Therapeutics (Primary)
- Indications Diabetic foot; Wounds
- Focus Therapeutic Use
- Sponsors Osiris Therapeutics
- 06 Oct 2016 According to a Osiris Therapeutics media release, the company will present data from this study at the Symposium on Advanced Wound Care (SAWC) Fall Conference.
- 04 Mar 2016 Results published in Grafix media release.
- 01 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.